A 20-Year-Old Cancer Vaccine Reveals New Clues to Durable Immunity and Long-Term Survival

More than 2 decades after its development, an early experimental cancer vaccine is offering hope for strategies to induce durable antitumor immunity.

Historically, cancer vaccines have failed to achieve consistent clinical success, especially in metastatic disease, due to the complex immunosuppressive environment cultivated by tumors.¹ However, emerging research data reveal that some patients vaccinated years ago may maintain persistent antitumor immune memory and suggest methods to dramatically enhance vaccine effectiveness.²

To understand why a small cohort of patients exhibited unusually prolonged survival following a breast cancer vaccine trial, researchers at Duke University School of Medicine revisited long-term immune responses. Surprisingly, the immune profiling showed that all the participants were still living 20 years after vaccination, something that is highly unlikely in the case of metastatic breast cancer. The immune cells retained the ability to recognize tumor antigens and, in particular, carried the costimulatory molecule CD27 on their surface.¹

“We were stunned to see such durable immune responses so many years later,” said Zachary Hartman, PhD, senior author of the study and an associate professor in the departments of surgery, integrative immunology, and pathology at Duke University School of Medicine. “It made us ask: What if we could boost this response even more?”³

Shifting the Focus to CD4+ T Cells and Memory Signals

Initial efforts in traditional cancer vaccine development focused on activating CD8+ cytotoxic T cells, which are considered the primary effector cells in the killing of cancer cells. However, studies into this old vaccine’s durable immune memory showed the vital role of CD4+ T cells, considered “helper” cells, as the key mechanisms of long-lasting antitumor immune response.¹

The CD27 marker emerged as a key signal in sustaining long-lived immune responses, prompting researchers to explore whether targeted stimulation of this pathway could improve vaccine efficacy.¹

“This study really shifts our thinking,” Hartman said. “[Its data] show that CD4+ T cells aren’t just supporting actors; they can be powerful cancer fighters in their own right and are possibly essential for truly effective antitumor responses.”³

Combining CD27 Signaling With Vaccine Enhances Tumor Regression

To determine whether increased CD27 activation could lead to better therapeutic results, the researchers conducted preclinical studies combining a vaccine targeting the HER2 protein—a tumor-associated antigen commonly overexpressed in breast cancer—with a CD27-targeting stimulatory antibody in multiple mouse models.

Almost 40% of the mice that received the combination treatment had complete tumor regression, compared with only about 6% in those given the vaccine alone.¹ This nearly 6-fold increase highlights the likely synergistic effect of antigen-specific vaccination and targeted costimulatory signals.

A deeper mechanistic study also revealed that the CD27-activating antibody boosted the function of CD4+ T cells, therefore enhancing their ability to orchestrate widely diverse antitumor responses.⁴

Importantly, the CD27 antibody was used only once at the same time as the vaccine, and elicited a long-lasting effect, suggesting a promising, simplified clinical translation approach.⁴

In addition, the use of a second antibody intended to potentiate CD8+ T cells after that resulted in tumor rejection in up to 90% of mice, indicating that rational combination immunotherapies can drive powerful antitumor responses beyond what either component achieves alone.³

Implications for Future Cancer Therapies

For oncology pharmacists, understanding these immunologic mechanisms is critical, especially given the growing prevalence of combination immunotherapy regimens. Pharmacists may be at the forefront of managing immune-related adverse events, determining the optimal sequencing of therapy with other treatments, such as immune checkpoint inhibitors, and educating patients on the scientific basis of new vaccine-based treatment strategies.

Although clinical translation will require rigorous evaluation in human studies, revisiting historic vaccine responses with modern immunologic insights may finally unlock the potential of cancer vaccines to improve long-term survival in patients with advanced malignancies.

REFERENCES

1. A 20-year-old cancer vaccine may hold the key to long-term survival. ScienceDaily. January 30, 2026. Accessed February 24, 2026. https://www.sciencedaily.com/releases/2026/01/260128075345.htm

2. Hwang BJ, Crosby EJ, Severson DT, et al. CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunity. Sci Immunol. 2025;10(114):eadz2294. doi:10.1126/sciimmunol.adz2294

3. Could a cancer vaccine developed long ago hold the key to long-term survival? Duke Health. October 28, 2025. Accessed February 24, 2026. https://corporate.dukehealth.org/news/could-cancer-vaccine-developed-long-ago-hold-key-long-term-survival

4. Hwang BJ, Crosby EJ, Severson DT, et al. CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunity. Sci Immunol. 2025;10(114):eadz2294. doi:10.1126/sciimmunol.adz2294